has very important biologic effects including cell differentiation, inhibition of proliferation and immune modulation (4) . There are several studies on the relationship between vitamin D levels and viral infections (5, 6) . It has been shown that vitamin D presents its antimicrobial activity by expression of cathelicidin (LL-37) (7, 8 2 vitamin D) induces cathelicidin releasing from the neutrophil granules via the vitamin D receptors (VDR). Cathelicidin primarily target enveloped virus by disrupting the lipid membrane of the envelope and also block the viral entry into the host cell (9) . The relationship between treatment response and low vitamin D levels are shown in hepatitis C virus (HCV) infections but there are not many studies investigating the relationship of hepatitis B (10, 11) .
Our aim in this study was to see whether or not there is a relationship between vitamin D levels and chronic HBV infection.
Materials and Methods

Patients
Ninety patients who were admitted to the infectious diseases outpatient clinic with the diagnosis of chronic hepatitis B (HbsAg positive, anti-Hbs negative for at least six months) between January and March 2013 were enrolled as cases. Similar group of 79 patients without a history or serological proof of chronic HBV infection and chronic diseases admitted to the outpatient clinic were chosen as controls retrospectively. People with calcium or vitamin D replacement therapy, chronic renal disease, heart failure, bone diseases, thyroid diseases and infectious diseases, such as hepatitis C and HIV were excluded. Demographics of the patients and controls were recorded. Treatments and responses were also investigated for the chronic HBV infection patients.
Blood samples were taken into EDTA tubes from the patients for detection of serum 25-hydroxy vitamin D (25(OH)D) levels. Serum 25(OH)D levels were measured with chromatographic method using a Shimadzu LC 20AD/T series (Kyoto, Japan) HPLC device in our hospital central laboratory. Normal values of 25(OH)D levels were 10-69 ng/ml in the study period. 25(OH)D values under 10 ng/ml were considered as vitamin D insufficiency.
Normality distribution of variables was tested with the Kolmogorov-Smirnov test. Student-t test was used for normally distributed variables and the Mann-Whitney U test was used for the analysis of variables not showing normal distribution. Chi-Square and Fischer's exact test were used for analysis of categorical variables. Spearman's correlation coefficient was used for correlation analysis. Data were shown as mean ± standard deviation (SD), median, number (n) and percent (%). STATA 12.0 program was used for data analysis and a p level of less than 0.05 was considered statistically significant.
Results
Ninety cases and 76 controls were included in the period of study. Thirty-three (43.4%) of the controls and 39 (43.3%) of the case group were male. Genders were similar in case and control groups (p=0.991). The mean age of the case and control groups were, 39.9±13.3 years and 43.0±13.3 years, respectively and there was no statistically significant difference between the groups (p=0.135) ( Table 1) .
Vitamin D levels in the case and control groups were; 11.7±6.6 ng/ml, 16.2±8.7 ng/ml, respectively. Vitamin D levels were significantly lower in the case group (p<0.001) than in controls ( Figure 1 ). When categorized as normal and insufficient, 25(OH)D levels were significantly lower in the case group (p<0.001, Odds Ratio (OR): 4.05, 95% GA: 1.98-8.26) ( Table 1 ). There was no difference in vitamin D levels between genders; 13.6±5.7 ng/ml in males and 13.9±9.3 ng/ml in females (p=0.846).
In the case group, 21 of 90 patients were on antiviral treatment. Twelve patients were on tenofovir (57.1%), four were on entecavir 0.5 mg (19%), two were on entecavir 1 mg (9.5%), two were on telbivudine (9.5%) and one was on lamivudine (4.8%). There was no difference between age of patients having treatment and not having treatment (p=0.069). There were more male patients in the treatment group (p=0.016). Vitamin D levels were higher in the treatment group, however, the difference was not statistically significant (14.0±6.9 ng/ml vs. 11.0±6.3 ng/ ml) (p=0.069). Vitamin D levels and demographic features of these groups are showed in Table 2 . There was no correlation between vitamin D levels and HBV DNA levels (Figure 2 ).
Of the chronic HBV patients, 12 were HBeAg positive and 76 were negative, two patients' condition was unknown. Vitamin D levels in HBeAg-positive and negative patients were 14.94±5.62 ng and 10.89±5.62 ng, respectively and there was no statistically significant difference (p=0.153).
Liver biopsy was performed in only 12 patients. There was no relationship between vitamin D levels and histological activity index (p=0.997). There was no relationship between fibrosis and vitamin D levels (p=0.425).
Discussion
The antimicrobial effect of vitamin D is thought to be via secretion of cathelicidin (in LL-37 form), human betadefencin-2 and reactive radicals of oxygen (9) . LL-37 shows bactericidal effect by shivering the bacterial membrane by electrostatic interaction. Similar effect can occur on lipid envelopes of the viruses (12) . Most of the studies revealing the positive effect of vitamin D on immunity were about infections caused by enveloped viruses (9) . Theoretically, molecules occurred through vitamin D should have antimicrobial effect on HCV and HBV because of their being enveloped.
There are studies in the literature about the relationship between vitamin D and chronic hepatitis, particularly hepatitis C. In the study by Bitetto et al. (10) the treatment response with standard interferon and ribavirin was worse in hepatitis C patients with vitamin D levels lower than 10 ng/ml. Petta et al. (11) found a relationship between liver fibrosis and vitamin D levels in addition. In our study, we believe that because of the low rates of liver biopsy, we could not find any relationship between vitamin D levels and histological activity index and fibrosis.
Vitamin D affects the calcium metabolism and immunity through the VDR (13) . A case-control study from Gambia performed on 2015 people identified that polymorphism caused by a base change in the 352 th codon of VDR receptor gene plays a role in hepatitis B being chronic. The identification of the role of receptor polymorphism in chronic hepatitis B makes us think that low serum levels of 25(OH)D may have an effect on the course of chronic hepatitis B (14) . Thus, in the study by Demir et al. (15) , 25(OH)D levels were significantly lower in the case group than in the immune and healthy control groups. Similarly, we found that chronic HBV patients had lower levels of 25(OH) D than the control group. Besides, our levels were also lower than in a study by Uçar et al. (16) investigating vitamin D levels in the general population (mean 25(OH)D levels in females and males were 24.02±16.93 and 22.76±8.52, respectively).
Farnik et al. (17) stated that low levels of 25(OH)D was the predictor of high viral replication and showed that 25(OH)D levels were significantly lower in patients with HBV DNA levels >2000 IU/ml. Besides, 25(OH)D levels were significantly lower in patients who were HBe antigen positive. In our study, we did not find a correlation between HBV DNA levels and 25(OH)D levels. There was also no relationship between vitamin D levels and HBe antigen status. Low patient number and seasonal change of vitamin D levels were thought to be the reasons for the lack of correlation. Some limitation should be considered when evaluating our study. First of all, not having naturally immune people as controls prevents us to show the effect of vitamin D on chronicity of hepatitis B. Since vitamin D works through VDR, not looking at the gene polymorphism for VDR could have lead to some patients' being overlooked even if they had immune deficiency for hepatitis B.
As a result, even though we determined that 25(OH)D levels were lower in chronic hepatitis B patients, prospective multicenter randomized controlled studies designed in order to show if these low levels cause difference in the course of the disease, development of complications like cirrhosis or hepatocellular cancer or to treatment response, will help gathering scientific knowledge with higher evidence level. 
